- Home
- MTNB vs XAIR Comparison
MTNB vs XAIR Comparison
Compare MTNB & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- XAIR
- Stock Information
- Founded
- MTNB 2013
- XAIR 2011
- Country
- MTNB United States
- XAIR United States
- Employees
- MTNB N/A
- XAIR N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- MTNB Health Care
- XAIR Health Care
- Exchange
- MTNB Nasdaq
- XAIR Nasdaq
- Market Cap
- MTNB 16.1M
- XAIR 18.2M
- IPO Year
- MTNB N/A
- XAIR N/A
- Fundamental
- Price
- MTNB $3.66
- XAIR $0.39
- Analyst Decision
- MTNB
- XAIR Strong Buy
- Analyst Count
- MTNB 0
- XAIR 4
- Target Price
- MTNB N/A
- XAIR $3.67
- AVG Volume (30 Days)
- MTNB 40.3K
- XAIR 945.9K
- Earning Date
- MTNB 11-06-2024
- XAIR 11-11-2024
- Dividend Yield
- MTNB N/A
- XAIR N/A
- EPS Growth
- MTNB N/A
- XAIR N/A
- EPS
- MTNB N/A
- XAIR N/A
- Revenue
- MTNB N/A
- XAIR $1,783,000.00
- Revenue This Year
- MTNB N/A
- XAIR $640.47
- Revenue Next Year
- MTNB N/A
- XAIR $286.81
- P/E Ratio
- MTNB N/A
- XAIR N/A
- Revenue Growth
- MTNB N/A
- XAIR 2922.03
- 52 Week Low
- MTNB $2.95
- XAIR $0.30
- 52 Week High
- MTNB $21.50
- XAIR $2.61
- Technical
- Relative Strength Index (RSI)
- MTNB 47.97
- XAIR 46.67
- Support Level
- MTNB $3.10
- XAIR $0.32
- Resistance Level
- MTNB $4.25
- XAIR $0.52
- Average True Range (ATR)
- MTNB 0.25
- XAIR 0.05
- MACD
- MTNB 0.14
- XAIR 0.00
- Stochastic Oscillator
- MTNB 54.66
- XAIR 22.12
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About XAIR Beyond Air Inc.
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.